Oncology Learning Network

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell lymphoma, supporting this regimen as a potential new frontline standard of care regardless of molecular subtype.

Samantha Shenoy, NP, and Caitlin Costello, MD, discuss how oncology care teams can close the gap between recognizing a patient with multiple myeloma as a potential CAR T-cell therapy candidate and getting that patient to evaluation. The episode highlights referral readiness, documentation, shared-care coordination, and common barriers that can delay timely evaluation.

Samantha Shenoy, NP, and Caitlin Costello, MD, discuss how risk stratification, early relapse patterns, and changes in disease trajectory can help oncology care teams recognize when a patient with multiple myeloma may warrant consideration for cellular therapy, including CAR T-cell therapy. The episode highlights the role of nurses and advanced practice providers in identifying clinical shifts and...

Elias Jabbour, MD, MD Anderson Cancer Center, Houston, Texas, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

This podcast reviews current and emerging approaches to residual disease detection in diffuse large B-cell lymphoma, emphasizing the role of PET-CT imaging in assessing treatment response and predicting relapse risk. Dr. David Russler-Germain discusses the limitations of PET-CT and highlights growing evidence that ctDNA-based MRD testing may provide more accurate prognostic information and improve...

This podcast explores the principles and clinical applications of circulating ctDNA-based MRD testing in diffuse large B-cell lymphoma, including how personalized sequencing assays can detect microscopic residual disease with greater sensitivity than imaging. Dr. David Russler-Germain discusses the growing evidence supporting ctDNA MRD testing for prognostication and treatment monitoring, while al...

This podcast examines the clinical utility of ctDNA-based MRD testing in diffuse large B-cell lymphoma, focusing on its role in post-treatment risk stratification, relapse detection, and treatment decision-making. Dr. David Russler-Germain reviews evidence showing that ctDNA MRD testing provides stronger prognostic value and earlier detection of recurrence than PET-CT imaging, supporting its growi...

Guest host Cassie Kline, MD, MAS, presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating clinically meaningful endpoints into future trials, as they may better reflect real-world patient benefit than radiographic criteria alone. ...

Three cholangioscopy experts join Elena Violari, MD, RPVI for this episode of the SIO Corner.

Three cholangioscopy experts join Elena Violari, MD, RPVI for this episode of the SIO Corner.

Applications of AR in Interventional Oncology by HMP Global

Dania Daye, MD, PhD, joins the SIO Corner podcast to discuss the ways AI may be applied in interventional oncology.

Petros Grivas, MD, PhD, discusses the combination of sacituzumab govetican and pembrolizumab for metastatic urothelial carcinoma in the second-line setting.

On this episode of Blood Bytes, a hematology podcast produced by Oncology Learning Network, Steven Treon, MD, PhD, Director of the Bing Center for Waldenström’s macroglobulinemia at the Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School, Boston, sits down with Christian Buske, MD, Medical Director at the Comprehensive Cancer Center and the Institute of Experimental C...

Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.

Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.

Petros Grivas, MD, shares his treatment plan for a patient with metastatic urothelial cancer who has progressed following platinum-based chemotherapy.

Margherita Rimini, MD, discusses the potential link between BRCAness phenotype and response to platinum-based chemotherapy in cholangiocarcinoma.